MedPath

Remdesivir Recommended for EU Authorization as First COVID-19 Treatment

• The European Medicines Agency (EMA) has recommended Remdesivir for authorization in the EU, marking it as the first COVID-19 treatment to receive such a recommendation. • The CHMP recommends Remdesivir be used in adults and adolescents (12+) with pneumonia requiring supplemental oxygen. • A study showed Remdesivir-treated patients recovered in 11 days versus 15 days with a placebo, a 31% faster recovery. • Remdesivir, initially developed for Ebola, interferes with RNA virus replication and has shown success against coronaviruses in lab studies.

The European Medicines Agency (EMA) has recommended the antiviral drug Remdesivir for authorization in the European Union to treat patients with COVID-19. This marks Remdesivir as the first medicine for COVID-19 to be recommended for authorization in the EU.
The EMA's Committee for Human Medicines (CHMP) has suggested the drug be used on adults and adolescents aged 12 and over who are suffering from pneumonia and require supplemental oxygen.

Clinical Trial Results

Clinical data supporting the recommendation comes from a study indicating that patients treated with Remdesivir experienced a notably faster recovery. Specifically, coronavirus patients treated with Remdesivir recovered in 11 days, compared to 15 days for those who received a placebo. This represents a 31 percent faster recovery time for the treatment group. The study, sponsored by the U.S. National Institutes of Health, commenced in February and involved 1,063 patients across the U.S., Europe, and Asia.

Mechanism of Action

Remdesivir functions by interfering with an enzyme critical for RNA virus replication. Laboratory studies have demonstrated its effectiveness against coronaviruses. The drug was originally developed to treat Ebola during the outbreak in West Africa.

Context

Remdesivir has been mentioned by health officials as one of the most promising drugs to fight COVID-19.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

InflaRx's Gohibic (vilobelimab) Receives European Commission Approval for SARS-CoV-2-Induced ARDS

InflaRx's Gohibic (vilobelimab) has been granted marketing authorization in the EU for treating SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
This approval makes Gohibic the first and only treatment approved in the European Union for this specific condition, addressing a critical unmet need.

EMA Approves Ronapreve and Regkirona for COVID-19 Treatment

The European Medicines Agency (EMA) has approved Ronapreve, developed by Roche and Regeneron, for treating COVID-19 in patients over 12 who do not require oxygen and are at high risk of severe infection.
Regkirona, manufactured by Celltrion, has also been approved by the EMA for treating COVID-19 in adults who do not require oxygen and are at high risk of severe infection.

European Medicines Agency Recommends Approval of Gohibic for SARS-CoV-2-Induced ARDS

The European Medicines Agency (EMA) has recommended the approval of Gohibic for treating SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
Gohibic offers a new therapeutic option for ICU patients suffering from ARDS caused by SARS-CoV-2, addressing a critical unmet need.

InflaRx Receives EMA Recommendation for Vilobelimab in COVID-19 Treatment

The European Medicines Agency (EMA) has recommended conditional marketing authorization for InflaRx's vilobelimab to treat COVID-19 in adult patients requiring invasive mechanical ventilation.
Vilobelimab is a first-in-class monoclonal antibody that selectively inhibits the complement factor C5a, a key mediator of inflammation in severe COVID-19.

InflaRx's Gohibic Receives EMA Panel Nod for COVID-19 ARDS Treatment

InflaRx's Gohibic (vilobelimab) received a positive opinion from the EMA's CHMP for treating adults with SARS-CoV-2-induced ARDS on mechanical ventilation and systemic corticosteroids.
The CHMP's recommendation is based on the Phase 3 PANAMO trial, which demonstrated a 23.9% relative reduction in 28-day all-cause mortality compared to placebo.

EMA Approves Pfizer's Paxlovid, First Oral Antiviral for COVID-19 in EU

The European Medicines Agency (EMA) has granted conditional authorization for Pfizer's Paxlovid, making it the first oral antiviral drug approved for COVID-19 treatment in the EU.
Paxlovid is recommended for adults with COVID-19 who do not require supplemental oxygen and are at high risk of severe illness, offering a new treatment option.

FDA Grants Emergency Use Authorization for Vilobelimab in Treating Critically Ill COVID-19 Patients

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, for the treatment of critically ill COVID-19 patients requiring invasive mechanical ventilation or extracorporeal membrane oxygenation. This authorization is based on the results of the Phase III PANAMO trial, which demonstrated a significant reduction in 28-day all-cause mortality.

FDA Approves Remdesivir as First Official COVID-19 Treatment

The FDA has granted full approval to remdesivir, making it the first and only drug with federal approval for treating COVID-19.
Remdesivir, an antiviral medication developed by Gilead Sciences, is administered intravenously to hospitalized COVID-19 patients.

NIH Initiates Clinical Trial of Remdesivir for COVID-19 in the U.S.

The National Institute of Health (NIH) has begun a clinical trial of Gilead Sciences' remdesivir to treat COVID-19 in U.S. hospitals.
The first participant is an American patient at the Nebraska Medical Center, who was quarantined from the Diamond Princess cruise ship.

Reference News

[1]
Remdesivir becomes the first drug for COVID-19, recommended for use in the EU - Telegrafi
telegrafi.com · Nov 13, 2024

EMA recommends Remdesivir for COVID-19 treatment in EU; CHMP to test in adults/adolescents with pneumonia requiring oxyg...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy